Ticker > Company >

Dr. Lal Pathlabs share price

Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB BSE: 539524 SECTOR: Hospital & Healthcare Services  253k   1k   317

2959.60
-9.80 (-0.33%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 2963.5

Today's Low

₹ 2913.65

52 Week High

₹ 3645

52 Week Low

₹ 2295.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

24794.2 Cr.

Enterprise Value

24026.66 Cr.

No. of Shares

8.38 Cr.

P/E

49.86

P/B

11.93

Face Value

₹ 10

Div. Yield

0.81 %

Book Value (TTM)

₹  248.02

CASH

767.54 Cr.

DEBT

0 Cr.

Promoter Holding

53.91 %

EPS (TTM)

₹  59.36

Sales Growth

10.66%

ROE

25.99 %

ROCE

31.99%

Profit Growth

43.42 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.66%
3 Year7.77%
5 Year13.05%

Profit Growth

1 Year43.42%
3 Year12.93%
5 Year17.38%

ROE%

1 Year25.99%
3 Year21.9%
5 Year23.65%

ROCE %

1 Year31.99%
3 Year27.18%
5 Year29.73%

Debt/Equity

0

Price to Cash Flow

45.92

Interest Cover Ratio

29.898

CFO/PAT (5 Yr. Avg.)

1.28920991536632

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 53.91 0.00
Dec 2024 53.91 0.00
Sep 2024 53.92 0.00
Jun 2024 54.60 0.00
Mar 2024 54.60 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 83.334 Cr.
  • Company has been maintaining healthy ROE of 21.8956333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 27.1777% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 29.898.
  • The Company has been maintaining an effective average operating margins of 27.2535199702361% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -129.6342 days.
  • Company has a healthy liquidity position with current ratio of 3.2883.
  • The company has a good cash flow management; CFO/PAT stands at 1.28920991536632.
  • The company has a high promoter holding of 53.91%.

 Limitations

  • The company has shown a poor revenue growth of 7.76946974408717% for the Past 3 years.
  • The company is trading at a high PE of 49.86.
  • The company is trading at a high EV/EBITDA of 30.9252.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 520.9 534.5 583.9 528.1 577.2
Total Expenditure 383.3 379 399.4 382.7 418.1
Operating Profit 137.6 155.5 184.5 145.4 159.1
Other Income 16.5 28.8 22 29.5 25.2
Interest 6.3 5.5 5 4.8 4.8
Depreciation 34.6 17.8 18.2 18.9 34.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 113.2 161 183.3 151.2 144.9
Tax 32.4 38.1 48.1 36.7 -3.5
Profit After Tax 80.8 122.9 135.2 114.5 148.4
Adjusted EPS (Rs) 9.67 14.72 16.17 13.7 17.75

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1490.56 1878.79 1769.03 2125.06 2351.62
Total Expenditure 1083.18 1366.32 1308.33 1544.45 1686.21
Operating Profit 407.38 512.47 460.7 580.61 665.41
Other Income 51.27 53.1 46.6 66.3 111.52
Interest 14.83 28.63 34.38 28.6 21.5
Depreciation 69.78 75.94 82.09 135.79 134.15
Exceptional Items 0 0 0 0 0
Profit Before Tax 374.04 460.99 390.83 482.53 621.28
Tax 93.94 115.74 98.47 135.8 124.02
Net Profit 280.11 345.25 292.36 346.73 497.26
Adjusted EPS (Rs.) 33.61 41.42 35.07 41.54 59.49

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 83.35 83.35 83.37 83.48 83.59
Total Reserves 1133.74 1388.77 1606.5 1717.24 2050.64
Borrowings 0 166.67 83.33 0 0
Other N/C liabilities 76.83 90.73 82.26 53.98 13.75
Current liabilities 252.25 451.04 432.16 450.47 388.44
Total Liabilities 1546.16 2180.55 2287.62 2305.18 2536.42
Assets
Net Block 300.07 370.95 361.48 1070.7 1017.83
Capital WIP 5.51 14.45 2.97 3.95 3.48
Intangible WIP 3.48 0 1.97 1.7 0
Investments 120.4 1061.81 1072.03 112.94 113.94
Loans & Advances 23.87 24.33 19.89 27.92 22.92
Other N/C Assets 3.53 9.71 19.11 51.57 100.98
Current Assets 1089.3 699.31 810.17 1036.39 1277.28
Total Assets 1546.16 2180.55 2287.62 2305.18 2536.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 374.04 460.99 390.83 482.53 621.28
Adjustment 59.1 87.81 96.31 120.22 74.79
Changes in Assets & Liabilities 37.33 -5.55 39.52 29.67 -1.44
Tax Paid -97.12 -117.53 -99.13 -127.82 -154.63
Operating Cash Flow 373.36 425.73 427.53 504.6 540
Investing Cash Flow -195.19 -448.53 -288.47 1.17 -293
Financing Cash Flow -135.74 141.24 -270.05 -410.53 -324.75
Net Cash Flow 42.42 118.43 -130.99 95.24 -77.75

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 54.60 54.60 53.92 53.91 53.91
anjaneya lal - 2.02 2.02 2.02 2.02
archana lal erdmann 2.03 2.03 1.85 1.85 1.85
arvind lal - 31.28 30.81 30.80 30.80
vandana lal - 19.26 19.24 19.24 19.24
anjaneya lal 2.02 - - - -
arvind lal 31.28 - - - -
vandana lal 19.27 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 45.40 45.40 46.08 46.09 46.09
hdfc trustee company limi... - 2.99 3.30 2.92 3.23
indus india fund (mauriti... - - - - 1.02
invesco oppenheimer inter... 3.80 3.73 3.56 3.56 3.52
life insurance corporatio... 1.47 1.47 1.47 1.47 1.47
llp 0.03 0.03 0.03 0.02 0.02
nippon life india trustee... - - - - 1.68
sbi large & midcap fund - 1.01 1.76 1.65 1.70
smallcap world fund, inc - - - 1.18 1.47
the brown capital managem... - - - - 1.34
uti-flexi cap fund - - - - 2.32
om prakash manchanda 1.16 1.08 1.04 1.01 -
uti flexi cap fund 3.07 2.82 2.30 2.06 -
first sentier investors i... 1.14 1.10 1.10 - -
al mehwar commercial inve... 1.06 1.02 - - -
wasatch emerging india fu... 1.02 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit CARE
Credit CARE
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY ACTION
Research HDFC Securities
Research Prabhudas Lilladhar

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY24
Concall Q4FY22
Concall Q4FY21
Concall Q4FY20
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY22
Concall Q2FY21
Concall Q1FY22
Concall Q1FY21
Concall Q1FY20
Concall Q3FY20
TYPE QUARTER ACTION
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY21
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY25
Presentation Q2FY25
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY20
Presentation Q3FY20

Company News

Dr. Lal Pathlabs Stock Price Analysis and Quick Research Report. Is Dr. Lal Pathlabs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Lal Pathlabs and its performance over the period of time. Dr. Lal Pathlabs stock price today is Rs 2953.4.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Dr. Lal Pathlabs cash from the operating activity was Rs 539.999 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Lal Pathlabs has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Lal Pathlabs , the EPS growth was 43.2194 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Lal Pathlabs has OPM of 28.2957031656968 % which is a good sign for profitability.
     
  • ROE: Dr. Lal Pathlabs have a healthy ROE of 25.986 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Dr. Lal Pathlabs is Rs 2953.4. One can use valuation calculators of ticker to know if Dr. Lal Pathlabs share price is undervalued or overvalued.
Last Updated on:
Brief about Dr. Lal Pathlabs
X